MBC-11 (trisodium)

• Description:

  MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mbc-11-trisodium-salt.html

• Solubility:

  H2O : 125 mg/mL (ultrasonic)

• Smiles:

  CC(P(O[Na])(O[Na])=O)(P(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)(O[Na])=O)O

• Molecular Formula:

  C11H17N3Na3O14P3

• Molecular Weight:

  577.15

• References & Citations:

  [1]Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47 (1) :12-22.|[2]Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24 (3) :303-e102.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [387877-45-4]